CIK 0001515673
- Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272546083
- Phone
- +1 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $127,561
- in 3 filings, $17K under 10b5-1 plans
Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-05-06 | Huang Dennis Karl EVP & Chief Tech Ops Officer | Sale | −363 | $113.68 | $41K | 40,506 |
| 2021-05-06 | Parschauer Karah Herdman EVP and General Counsel | Sale | −313 | $113.67 | $36K | 29,997 |
| 2021-05-06 | Pinion John Richard See Remarks | Sale | −363 | $113.69 | $41K | 50,122 |
| 2021-05-06 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Sale | −142 | $113.67 | $16K | 15,031 |
| 2021-05-06 | Kassberg Thomas Richard CBO & EVP | Sale | −363 | $113.69 | $41K | 106,818 |
| 2021-05-06 | KAKKIS EMIL D President & CEO | Shares withheld for taxes | −852 | $115.71 | $99K | 595,200 |
| 2021-05-06 | Harris Erik EVP & Chief Commercial Officer | Sale | −307 | $113.68 | $35K | 27,110 |
| 2021-05-06 | Bedrosian Camille L EVP and Chief Medical Officer | Sale | −364 | $113.67 | $41K | 38,775 |
| 2021-05-03 | KAKKIS EMIL D President & CEO | Sale | −30,000 | $107.80 | $3.2M | 2,259,741 |
| 2021-04-20 | Harris Erik EVP & Chief Commercial Officer | Sale | −396 | $104.28 | $41K | 27,417 |
| 2021-04-16 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Grant or award | +1,500 | 15,044 | ||
| 2021-04-15 | Bedrosian Camille L EVP and Chief Medical Officer | Option exercise | +5,000 | $55.00 | $275K | 44,139 |
| 2021-04-15 | Bedrosian Camille L EVP and Chief Medical Officer | Sale | −5,000 | $109.09 | $545K | 39,139 |
| 2021-04-15 | Bedrosian Camille L EVP and Chief Medical Officer | Option exercise · Stock Option | −5,000 | 58,000 | ||
| 2021-03-08 | Huizenga Theodore Alan SVP, Controller and PAO | Sale | −3,000 | $120.69 | $362K | 13,544 |
| 2021-03-01 | Kassberg Thomas Richard CBO & EVP | Grant or award | +5,500 | 106,978 | ||
| 2021-03-01 | Kassberg Thomas Richard CBO & EVP | Grant or award | +4,636 | 111,614 | ||
| 2021-03-01 | Kassberg Thomas Richard CBO & EVP | Sale | −4,572 | $138.17 | $632K | 107,181 |
| 2021-03-01 | Kassberg Thomas Richard CBO & EVP | Grant or award · Stock Option (Right to Buy) | +11,000 | 11,000 | ||
| 2021-03-01 | Pinion John Richard See Remarks | Grant or award | +5,500 | 51,799 |
Page 20 of 21 · 410 trades